Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpicilib + Abiraterone in mCRPC
NCT06500247Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Qilu Hospital of Shandong University. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06500247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500247.